Prostate cancer (PC) is one of the most common cancers and is a leading cause of death.
Its initial growth is dependent on androgens; most patients show an initial response to hormonal therapy but will experience disease progression when PC becomes resistant to castration. In 2004, two key randomized controlled trials demonstrated a benefit for docetaxel-based regimens in the treatment of men with castration-resistant prostate cancer (CRPC). Cabazitaxel (XRP6258, TXD258, and RPR116258A), a tubulin-binding taxane drug as potent as docetaxel in cell lines, was the first treatment able to prolong survival for metastatic CRPC in the post-docetaxel setting. This review describes pharmacologic parameters of this agent followed by a review of clinical trials involving cabazitaxel. Other available treatments and the place of cabazitaxel in metastatic CRPC setting are discussed.
Written by:
Calcagno F, Nguyen T, Dobi E, Villanueva C, Curtit E, Kim S, Montcuquet P, Kleinclauss F, Pivot X, Thiery-Vuillemin A. Are you the author?
Centre Hospitalier Universitaire Besançon, Oncology, Besançon, France.
Reference: Clin Med Insights Oncol. 2013;7:1-12.
doi: 10.4137/CMO.S7256
PubMed Abstract
PMID: 23362372
